First-pass extracted concept

engineered modulation of gene expression or cytokine secretion in CAR cells

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This engineering strategy modifies gene expression or cytokine secretion to improve CAR-cell persistence and antitumor activity.

Source 1DOI PubMed

Resources required

The abstract supports that gene-expression or cytokine-secretion engineering is required, but does not specify the exact payloads or circuits.

Source 1DOI PubMed

What problem it solves

It is presented as a way to improve persistence and antitumor function of CAR therapies in AML.

Source 1DOI PubMed

What it does not solve

The abstract does not show that this strategy directly resolves AML antigen overlap with healthy hematopoietic cells.

Source 1DOI PubMed

Alternatives

The abstract mentions logic-gated CARs, controllable/suicide-switch systems, adapter CAR platforms, and alternative immune cells as other approaches.

Source 1DOI PubMed

Evidence Snippets

Adapter CAR platforms allow real-time, flexible targeting, while engineered modulation of gene expression or cytokine secretion enhances persistence and antitumor activity.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1capabilitysupports2025Source 1DOI PubMed

Engineered modulation of gene expression or cytokine secretion enhances persistence and antitumor activity.

Quoted textsource-backed

engineered modulation of gene expression or cytokine secretion enhances persistence and antitumor activity

Claim 2limitationsupports2025Source 1DOI PubMed

CAR T-cell therapy in AML has been limited by early relapses and severe toxicities.

Quoted textsource-backed

its application in AML has been limited by early relapses and severe toxicities

Claim 3mechanism or rationalesupports2025Source 1DOI PubMed

Most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating risks of on-target/off-tumor toxicity and prolonged myeloablation.

Quoted textsource-backed

most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating significant risks of on-target/off-tumor toxicity and prolonged myeloablation